Background: The study aims to evaluate the expression and activity of glycogen synthase kinase 3 isoforms α/β (GSK3α/β) and to assess their oncogenic potential through a correlation with the expression of cyclin D1 and p53 in oral cancer.
Introduction
Oral cancer is the sixth most common cancer in the world, and its incidence varies in different ecogeographic regions [1, 2] . While tobacco smoking and alcohol consumption are major risk factors for oral cancer in the western population, betel quid chewing with tobacco is recognized as the predominant contributor to oral cancer prevalence in Southeast Asia [3] . The high incidence of oral cancer in the Jharkhand state in the eastern part of India may be attributed to use of locally made alcoholic beverages, such as Mohua prepared from the flowers of the mahua plant, and Hadia prepared from fermented cereals, in addition to tobacco chewing habit.
Glycogen synthase kinase 3, a serine/threonine kinase involved in multiple physiological processes is a highly conserved and ubiquitously expressed member of the CMGC family of protein kinases [4] . To date, two members of the mammalian GSK3 family (α and β) are known. GSK3α/β plays a major role in epithelial cell homeostasis [5] . GSK3 proteins usually have three domains, a small N-terminal domain, a slightly larger C-terminal domain and a predominant middle kinase domain. In addition to these domains, a nuclear localization sequence has also recently been identified [6] . Its paradoxical role as a tumor suppressor or a tumor promoter is actively under investigation in various neoplastic diseases [7] . GSK3 is a constitutively active enzyme in normal cells and undergoes rapid inhibition by stimuli. The activity of GSK3 is inhibited upon phosphorylation at Ser 21 of GSK3α and at Ser 9 of GSK3β [8] . GSK3 is a key suppressor of the canonical Wnt signaling pathway including β-catenin [9] and various other oncogenic transcription factors (OTFs), such as NFκB, AP-1, c-Myc and p53, which are involved in cell proliferation [10] .
Cyclin D1, a proto-oncogene, is an important regulator of G1 to S phase progression in many different cell types [11] . Together with its binding partners cyclin dependent kinase 4 and 6 (CDK4 and CDK6), cyclin D1 forms active complexes that promote cell cycle progression [12] . Cyclin D1 is important for the development and progression of several cancer types, including that of oral epithelial cancer that occurs by the transformation of the buccal mucosa causing oral squamous cell carcinoma (OSCC) [13] . Overexpression of cyclin D1 protein is frequently the result of its deregulation at the post-translational level. Active GSK3α/β phosphorylates cyclin D1, leading to its degradation [14] ; thus, suppressing signals that inactivate GSK3α/β causes epithelial cancer [15] . Alternatively, p53 is a well-known tumor suppressor protein that is widely reported in human cancer. Wild type p53 maintains genomic integrity through the induction of cell cycle and cell death regulatory genes in response to DNA damage [16] . Although mutational inactivation of p53 has been reported in nearly half of the oral cancer population, in the subpopulation of OSCC cases without p53 mutations the mechanism of p53 inactivation is still far from clear [17] . p53 activity is regulated by active GSK3β, due to either a physical association or phosphorylation and post-translational modifications [18] .
In the present study, an investigation was performed to assess the expression of GSK3α/β in various stages of oral tumor progression. The activity of GSK3α/β was also assessed by detecting its site-specific phosphorylation in various oral cancer samples, more elaborately in oral tongue SCC (OTSCC) samples. The protein interaction of GSK3α/β with cyclin D1 in various oral tumors was determined, and the inactivation status of GSK3α/β was correlated with the expression of pro-cell cycle promoting cyclin D1 and with the expression of p53 in a group of random samples. The data suggest that the inactivation of GSK3, especially GSK3β, might be related to oral cancer progression and might fuel the transcription of cyclin D1. These pathways may be targeted to treat this deadly disease.
Materials and methods

Patients and tissue samples
A total of one hundred seventy-nine (n = 179) different human oral tumors and control samples, which include tissue microarray (TMA, OR802 and OR601a from US Biomax) samples (n = 140) and freshly collected human oral tumor and control samples (n = 39), were analyzed. The fresh samples of twenty-seven oral tumor samples, six normal samples and six PMLs samples (thick leukoplakia n = 3; OSMF n = 3) were collected from local hospitals, nursing homes and clinics near the Ranchi area. These samples were collected after obtaining informed consent from the patients, and the use of human samples was approved by the Institutional Human Ethical Committee of CUJ. The samples of normal and PMLs were obtained from patients without cancer undergoing nononcologic surgical procedures. The collected samples were divided into two pieces and stored in liquid nitrogen and buffered formalin. H&E sections were used to confirm the pathologic diagnosis and the presence of lesional and cancer tissue, verified by a pathologist. Staging of the oral cancer samples was conducted according to American Joint Committee on Cancer (AJCC)/International Union against Cancer (UICC) TNM classification after brief histological studies.
Immunohistochemistry (IHC)
IHC was performed with various oral tissue samples as described earlier with slight modifications [19] . Briefly, following dewaxing, washing and rehydration of the slides through xylene and graded alcohols, microwave heating in citrate buffer was used for antigen retrieval of GSK3α, GSK3β and pS 9 GSK3β; however for pS 21 GSK3α a high pH flex buffer was used. Endogenous peroxidase was blocked in peroxidase blocking solution (DAKO). Primary antibodies (Santa Cruz Biotechnology) p/GSK3α (dilution 1: 15) and p/GSK3β (dilution 1: 40) were incubated at 4°C overnight. The EnVision FLEX Mini Kit, High pH (Link) (Code: K8023; DAKO) was used for staining. The slides were then washed, and secondary antibody (FLEX-HRP) was applied as dictated by the manufacturer (DAKO Kit). Staining was visualized with diaminobenzidine tetrachloride (DAB). The sections were counterstained with hematoxylin, dehydrated, cleared and mounted. For a negative control, BSA was used in place of the primary antibody. A skin cancer sample known to overexpress GSK3α/β and pGSK3α/β protein was used as a positive control. The normal oral mucosa samples showed moderate immunoreactivity to GSK3α/β and faint immunoreactivity to the pGSK3α/β antibody. Hence, all of the immunostained cancer samples were visualized and scored, such as 0 (no staining), 1 (least intense and staining like normal), 2 (moderately intense staining) and 3 (maximum intense staining) based on the staining intensity and the extent of immunoreactivity. A score of 0 was considered no expression and a score of 1, 2, or 3 was considered for expression of the protein whereas a score of 2 or 3 was considered for the overexpression of the protein.
Western blot analysis
Western blot analysis was performed as described in detail previously [20] . Cancerous and control tissue lysates were prepared in RIPA buffer (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM β-Glycerophosphate; 1% Triton X-100; 2.5 mM Sodium pyrophosphate; 1 mM Sodium orthovanadate; 1 mM PMSF; 0.5% Sodiumdeoxycholate; 10nM Okadoic acid (freshly prepared); 1% SDS; Protease inhibitor (freshly prepared, 1X); Phosphatase inhibitor (freshly prepared, 1X)). Protein samples (60-100 μg) were separated using 10% SDS-PAGE along with a ColourBurst TM Electrophoresis Marker, Sigma (Catalog Number: C1992) and transferred to PVDF membranes using an iBlot TM dry blotting system (BioRad). The blots were cut according to the MW of the protein used for WB analysis. The immunoreactivity of GSK3α was observed much less than GSK3β and therefore a greater amount of tissue extract (TEs) and antibody concentration was used to detect the protein. sc-2768 and donkey anti-mouse IgG-HRP: sc-2314, were used against the respective primary antibody, and the SuperSignal (R) West Pico Chemiluminescent Substrate (Thermo Scientific) was used to detect horseradish peroxidase (HRP) on the immunoblots. A developer, fixer and X-ray film (Kodak) were used to capture the signal.
Immunoprecipitation and WB
Immunoprecipitation was performed as described previously [21] . Tumor extracts (n = 12) of different stages, T1/T2 (initial stage, n = 6) and T3/T4 (higher stage, n = 6) samples, were used to determine the association of GSK3α/β with cyclin D1. Immunoprecipitation assays were performed using 500 μg of tumor tissue extract (TE), 1 μg GSK3α/β antibody and Protein A/G PLUS-Agarose Immunoprecipitation Reagent (sc-2003, Santa Cruz Biotechnology). The samples were incubated for two hours at RT with shaking and after thorough washing, the immunoprecipitates were run and transferred to PVDF membranes and processed for immunoblotting using a cyclin D1 antibody.
RT-PCR analysis
Total RNA from 28 samples (6 normal, 6 PMLs and 16 tumor samples) were isolated using the Trizol reagent. The RNA concentration was determined from the OD at a wavelength of 260 nm. The ratio of absorbance at 260 nm and 280 nm was calculated and RNA samples with a ratio of 1.8 to 2.0 were considered pure and included in the study. In total, 5 μg of isolated total RNA was reverse-transcribed to cDNA in a reaction mixture containing 4 μl of 5X reaction buffer, 2 μl of a dNTPs mixture (10 mM 
Statistical analysis
The immunostained tissues samples were counted, and a score was given as described and summarized in Tables 1  and 2 . Fisher's exact test and the Chi-square test were used to draw any conclusion. The WB experiments were performed at least in triplicate. The bands were densitometrically analyzed, and the arbitrary units were used for the quantitative expression of various proteins, such as pS 21 GSK3α, pS 9 GSK3β, cyclin D1, and p53. The mean and SD of these arbitrary numbers were used to plot the graphs. Student's t-test was used to compare the differences in various groups. Similarly, the correlation of pS 21 GSK3α and pS 9 GSK3β expression with cyclin D1 and p53 expression of all of the samples were assessed via bivariate analysis using Pearson's/Spearman's coefficient. In all of the experiments, a p-value <0.05 was considered statistically significant.
Results
Protein expression of GSK3β is higher than GSK3α in different types of oral tumors GSK3 immunoreactivity was observed, and different tumors showed the expression of both of the proteins (GSK3α/β) to different extents. GSK3α/β protein expression was observed in the cytoplasmic, nuclear and both the cytoplasmic and nuclear regions of the cancer cells (Figure 1 ). In most of the samples, intense overexpression of GSK3β compared to GSK3α was observed. The age group >40 ≤ 70 showed expression and overexpression of GSK3β compared to GSK3α, and this observation was statistically significant (p = 0.03 and p = 0.0006, respectively). Similarly, the age group >70 showed more overexpression of GSK3β compared to the GSK3α isoform (p < 0.001). Males and females showed a greater overexpression of GSK3β compared to GSK3α (p < 0.0001 and p = 0.002, respectively). Both expression and overexpression of GSK3β compared to GSK3α was found independently of nodal invasion (p = 0.04 and p < 0.0001). The smaller sized oral tumors showed more expression (p = 0.006) and overexpression (p < 0.0001) of GSK3β compared to GSK3α. Similarly, GSK3β expression and overexpression was significantly higher than GSK3α expression and overexpression in non-metastatic (p = 0.03 & p < 0.0001) and metastatic oral tumors (p = 0.03 & p < 0.002), respectively. All of these independent observations demonstrate a higher expression level of GSK3β than GSK3α in oral tumor tissue samples (Table 1) .
GSK3α/β protein over-expression is significantly associated with OSCC
Various types of oral tumors and control samples (normal squamous epithelium, hyperplasia, cancer adjacent oral tissue, non-neoplastic oral cavity glands, adenoid cystic carcinoma, mucoepidermoid carcinoma, adamantinoma, basal cell carcinoma, OSCC, and acinic cell carcinoma) were analyzed to determine the expression of GSK3α/ β by IHC (summarized in Table 1 ). Normal oral mucosa, hyperplasia and various oral cancer samples showed immunoreactivity to both GSK3α/β antibodies to different extents according to the extent of differentiation but some samples did not show any reactivity. OSCC tissue samples of the cheek (Figure 1. A (a, b) ), gingiva (g, h), lower mandible (i, j), and lip (w, x) showed a more intense expression of GSK3β than GSK3α. Similarly, different oral SCC (b, h, j, x) samples showed maximum immunoreactivity to GSK3β. The tissue samples of most of the mucoepidermoid carcinoma showed expression of both GSK3α and GSK3β in ductal cells (c, d and q, r and u, v). The mandibular benign adamantinomas showed immunoreactivity to both GSK3α and GSK3β (e, f ). In tissue samples of adenoid cystic carcinoma, staining was not observed, either in ductal or in myoepithelial cells (k, l). The tissue samples of basal cell carcinoma showed very faint expression of both GSK3α and GSK3β (m, n), and acinic cell carcinoma showed no expression (o, p) of either GSK3α or GSK3β. In the normal salivary gland, staining was observed in the ductal cells only and more expression of GSK3α than GSK3β (s, t) was observed. Meanwhile, in total 33.75% (27/80) and 51.25% (41/80) of The expression of GSK3α was observed more in OSCC tumors than other types of tumors in the oral cavity (such as mucoepidermoid carcinoma, adenoid cystic carcinoma, basal cell carcinoma, adamantinoma, and acinic cell carcinoma considered together) (p = 0.02). Similarly, a significant difference was observed in the overexpression of GSK3β in OSCC tumors compared with other types of tumors as indicated in Table 1 (p < 0.0001; Figure 1B) . These results clearly demonstrate a greater role of GSK3β overexpression (which was later found to be mostly inactive) in OSCC.
The cellular expression and distribution of GSK3 was located within different cellular compartments. GSK3β expression was observed in eleven higher grade (MDSCC and PDSCC) tumors. It was expressed in the nuclear compartment (NC), the nuclear-cytoplasmic compartments (N-CC) (Figure 2A GSK3β in NC, N-CC and CC, respectively. The trend of GSK3β expression shifting from the cytoplasmic to the nuclear compartment according to disease severity was observed (p = 0.09, though was not significant due to sample size). Alternatively, among the five (5/14) positive tumors of a higher grade (MDSCC and PDSCC), the expression of GSK3α was observed in the NC, N-CC and CC in 2, 2 and 1 of the tumor samples, respectively. Likewise, in the lower grade tumor (WDSCC) samples, GSK3α expression was observed in various cellular compartments, including 5 samples that express it in only the NC, 3 samples in the N-CC and 9 samples in the CC.
The normal samples showed expression of GSK3β in the NC and CC in one sample (Figure 2A (a, b) ) and the expression of GSK3α in the NC and CC in two and one of the samples, respectively.
GSK3α and GSK3β protein expression pattern in the progression of OSCC
Statistics were gathered to determine the expression of GSK3α and GSK3β in OSCC progression. The results showed that in the normal lip, no immunoreactivity was observed for both the GSK3α and the GSK3β antibody ( Figure 3A (a, b) ). However, in the normal tongue tissue, mild expression of the GSK3α/β protein was observed in the peripheral epithelial layer in most of the cases ( Figure 3B  (a, b) ), except one sample that showed strong immunoreactivity to the GSK3β antibody. In the tissue samples with mild hyperplasia, the expression of GSK3α and GSK3β was observed, and it was limited to the deeper epithelial zone of both the lip and tongue tissues ( Figure 3A (c, d) & B (c, d) ). Alternatively, the expression of the GSK3α/β protein was observed in the tumors of the lip and tongue ( Figure 3A  (e, f) & B (e, f) ). In the OTSCC progression model, a total of twenty-two samples were analyzed, and GSK3β overexpression was observed in 14.2% (1/7) of normal samples, in 20.0% (1/5) of hyperplasia and 70.0% (7/10) of cancer samples (p = 0.0396). In the lip cancer progression model, a total of fifteen samples were analyzed and GSK3β overexpression was not observed in normal (n = 2) or hyperplasia (n = 3) samples but was observed in 70.0% (7/10) of cancer samples (p = 0.0376). In the distant metastatic SCC samples, the invasive cancer cells at the new location demonstrated an overexpression of GSK3β in 87.5% (7/8) whereas only 12.5% (1/8) of samples showed an overexpression of GSK3α (p = 0.002) ( Table 1 and Figure 3C (a to h)). Similarly, nearby lymph node positive cases were found in 60% (3/5) of the GSK3β overexpressing tumors and in only 20% (1/5) of the GSK3α overexpressing tumors. GSK3β in 42.8% (3/7) and 28.5% (2/7) of the samples (Figure 4. a, b) , respectively. However, the overexpression of pS 9 GSK3β was not observed in 85.7% (6/7) of cancer adjacent normal looking tongue samples. One tumor adjacent tongue sample with mild hyperplasia showed moderate expression of both pS 21 GSK3α and pS 9 GSK3β (Figure 4. c, d) 
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(p = 0.036). Meanwhile, in the age group >40 ≤ 70, the over-expression of inactive GSK3β compared to GSK3α 
Nuclear accumulation of pGSK3α/β protein expression in the OTSCC
The distribution of pS 9 GSK3β was observed in the nuclear, cytoplasmic or both cellular compartments in human OTSCC samples ( Figure 2B (a, b) ). Among the nine pS GSK3β-expressing tumors of a higher grade (MDSCC and PDSCC), pS 9 GSK3β expression was observed in the NC, N-CC and in only CC in 6, 2 and 1 samples, respectively. Alternatively, in the lower grade tumors (WDSCC), 8, 6 and 23 samples showed pS 9 GSK3β expression in the NC, N-CC and in only CC, respectively ( Figure 2B (a, b) ). This trend of pS 9 GSK3β expression shifting from the cytoplasmic to the nuclear compartment with tumor progression was significant (p = 0.01; Figure 2C ).
Alternatively, a faint reactivity of pS 21 GSK3α was observed in the OTSCC samples. Among the pS 21 GSK3α-stained five positive tumors of a higher grade (MDSCC and PDSCC), the expression in the NC, N-CC and only CC was observed in 3, 1 and 1 tumor samples, respectively. Similarly, in the lower grade tumors (i.e., WDSCC), 4, 7 and 18 tumor samples were positive for pS 21 GSK3α in the NC, N-CC and in only CC, respectively (p = 0.054).
Inactivation of GSK3α/β and their correlation with cyclin D1 and p53 in human OSCC
The expression of GSK3α/β, cyclin D1 and p53 (n = 39; Table 3 ) was detected using WB analysis. Detectable expression of GSK3α was observed in 83.3% normal (5/6), 66.6% PMLs (4/6), and 51.8% tumor samples (14/27) . Similarly, the expression of GSK3β was observed in 83.3% normal (5/6), 83.3% PMLs (5/6) and 59.25% oral tumor (16/27) correlation was observed when inactive GSK3β expression and cyclin D1 mRNA expression was compared. This observation may be due to the activation of some downstream TFs of GSK3β to fuel cyclin D1 expression and boost the uncontrolled cell division program in OSCC. p53 is the guardian of the genome and a well-known tumor suppressor, and its loss of function is the most frequent genetic event in human cancer [30, 31] . Although it is inactivated by a number of pathways, GSK3β is a key regulatory molecule of p53 [32] . GSK3 has been reported to phosphorylate p53 on Ser 33 -p53 or Ser 315 -p53 and Ser 376 -p53 and promote the acetylation of p53, thus controlling the function of p53 [18] . There are numerous studies on p53 expression in OSCC that are inconclusive [33] . However, the results of the present study indicate that p53 expression is higher in the subset of oral tumors with inactive GSK3. A positive correlation was observed between inactive GSK3 and p53 expression. Inactive GSK3 as a result of number of major signaling pathways including the phosphatidyl-inositol-3-kinase (PI3K) pathway, the Wnt pathway, Hedgehog signaling and Notch signaling, may modulate the status of many oncogenic TFs, RNA-binding proteins, miRNAs, and might be the cause of increased p53 expression in OSCC [34] [35] [36] . The exact molecular mechanism of GSK3β mediated p53 expression remains unexplored. Moreover, in parallel with the oral tumor progression, the nuclear accumulation of pS 9 GSK3β was observed, and this observation may be an impediment to activate p53 and may restrict uncontrolled cell division.
Finally, growth factor stimulation and oncogenic transformation may lead to increased glucose metabolism in the transformed oral mucosa that may increase the pool of inactive GSK3. This inactive GSK3 (mainly GSK3β) may initiate a signaling mechanism that promotes transcriptional activation of cyclin D1 by targeting some yet unknown TFs to fuel OSCC. Moreover, the inhibition of kinase activity and the shift in cellular compartments may affect the subpopulation of p53 that is not inactivated by a mutation (Figure 8 ). Our study strongly suggests that GSK3 expression may be used as a molecular marker for the diagnosis and therapeutic intervention of OSCC.
Conclusion
In summary, although increased expression of both GSK3α and GSK3β was associated with human oral tumor pathogenesis, progressive inactivation of GSK3β was observed in OSCC particularly in OTSCC. A positive correlation was observed between expression of pS 9 GSK3β and cyclin D1 protein expression, p53 protein expression and cyclin D1 mRNA expression in human oral cancer/ control tissue samples. Hence, the expression of pS 9 GSK3β can be used as a marker for assessing disease severity. Further research is warranted to elucidate the additional mechanisms involved so as to develop appropriate therapeutic interventions.
